Keywords
Infantil
Efeitos Adversos
Imunização
Sars-CoV-2
How to Cite
Abstract
Introduction: The recent COVID-19 pandemic has resulted in an unprecedented global health crisis. Fortunately, the race for the accelerated development of vaccines allowed a coping strategy that allowed the resumption of relative normality, but not before bringing other challenges with it. The adverse effects resulting from vaccination were one of the points of criticism for those who questioned the safety of the vaccines. Myocarditis, in particular, has often been cited as a justification for vaccine hesitancy. Objective: To analyze and answer the question: “Do COVID-19 vaccines cause myocarditis in children up to 12 years of age?” Methods: Integrative Literature Review, carried out on the Medical Publisher (PUBMED) search platforms; Virtual Health Library (VHL) and Brasil Scientific Electronic Library Online (SCIELO), using Health Sciences Descriptors (DeCS) in English associated with the use of the Boolean operator (AND) – "COVID-19 Vaccines" AND "Myocarditis" AND "Incidence" AND "Children", after applying the inclusion and exclusion criteria, twelve (12) articles were selected to constitute the research. Results: Although some studies show various adverse reactions, such as: mood changes, fatigue, sleep disturbances, pain at the injection site, fever, localized inflammation and arthralgia, the prevalence of myocarditis was not seen, which is more prevalent in patients with adjacent comorbidities (n=05; 41.6%). Conclusion: According to the selected studies, there is not enough scientific evidence to point out the relationship between vaccination against COVID-19 and the occurrence of adverse events, such as myocarditis, in children up to 12 years of age.
References
AHMED, S. K. Miocardite após vacinação contra BNT162b2 e mRNA-1273 COVID-19: relato de 7 casos. Ann Med Surg, 77:103657, 2022.
ASADUZZAMAN, M.; PURKAYASTHA, B; ALAM, M. M.; CHAKRABORTY, S. R.; ROY, S.; AHMED, N. Encefalopatia, miocardite e trombocitopenia associadas à vacina de mRNA COVID-19 com excelente resposta à metilprednisolona: um relato de caso. J Neuroimunol, 368:577883, 2022.
BOZKURT, B.; KAMAT, I.; HOTEZ, P. J. Myocarditis With COVID-19 mRNA Vaccines. Circulation, [s. l.], v. 144, n. 6, p. 471–484, 2021.
CASTRO, R.. Vacinas contra a Covid-19: o fim da pandemia?. Physis: Revista de Saúde Coletiva, [s. l.], v. 31, p. e310100, 2021.
CHOI, J. H.; CHOI, S. H.; YUN, K. W. Fatores de risco para COVID-19 grave em crianças: uma revisão sistemática e meta-análise. J Coreano Med Sci, 37:e35, 2022.
GALHARDI, C. P. et al. Fake news e hesitação vacinal no contexto da pandemia da COVID-19 no Brasil. Ciência & Saúde Coletiva, [s. l.], v. 27, p. 1849–1858, 2022.
GODDARD, K. et al. Incidence of myocarditis/pericarditis following mRNA COVID-19 vaccination among children and younger adults in the United States. Annals of internal medicine, v. 175, n. 12, p. 1169–1771, 2022.
GOMES, M. M. N. et al. Epidemiologia e gravidade da Miocardite induzida por vacina contra Covid-19 - uma revisão sistemática com comparação de dados nacionais. Brazilian Journal of Health Review, [s. l.], v. 6, n. 6, p. 33158–33177, 2023.
HAUSE, A. M. et al. Safety monitoring of Pfizer-BioNTech COVID-19 vaccine booster doses among children aged 5-11 years - United States, May 17-July 31, 2022. MMWR. Morbidity and mortality weekly report, v. 71, n. 33, p. 1047–1051, 2022.
HAUSE, A. M. et al. Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years. Pediatrics, v.150, n.2, 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35581698/. Acesso em: 13 jun. 2024.
HEIDECKER, B. et al. Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases. European journal of heart failure, v. 24, n. 11, p. 2000–2018, 2022.
HOPIA, H.; LATVALA, E.; LIIMATAINEN, L.. Reviewing the methodology of an integrative review. Scandinavian journal of caring sciences, v. 30, n. 4, p. 662-669, 2016.
HU, M. et al. Safety of Ancestral Monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 Vaccines in US Children Aged 6 Months to 17 Years. JAMA Netw Open, v.7, n.4, 2024. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11043896/. Acesso em: 13 jun. 2024.
JAINISTA, S. S. et al. Miocardite associada à vacinação COVID-19 em adolescentes. Pediatria, v. 148, n.5, 2021. Disponível em: https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357?ref=mattiaslindberg.com. Acesso em: 13 jun. 2024.
KIM, H.W. et al. Patients with Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol, v.6, n.10, p.1196-1201, 2021. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34185046/. Acesso em: 13 jun. 2024.
LIMA, E. J. da F.; LEITE, R. D. COVID-19 vaccination in children: a public health priority. Jornal de Pediatria, v. 99, n. S1, p. 28-36, 2023.
LIMA, N. T.; BUSS, P. M.; PAES-SOUSA, R. A pandemia de COVID-19: uma crise sanitária e humanitária. Cadernos de Saúde Pública, [s. l.], v. 36, p. e00177020, 2020. Disponível em: https://www.scielosp.org/article/csp/2020.v36n7/e00177020/pt/?utm_source=researc. Acesso em 09 de junho de 2024.
NURHANI, M. A. et al. COVID-19 vaccine safety and side effects in children aged 5-11 years: a cross-sectional study. Med J Malaysia, v. 78, n.6, p. 803-807, 2023. Disponível em: https://pubmed.ncbi.nlm.nih.gov/38031224/#:~:text=The%20most%20frequently%20reported%20side,such%20as%20anaphylaxis%20or%20myocarditis. Acesso em: 13 jun. 2024.
NYGAARD, U. et al. Risk of Myopericarditis After COVID-19 Vaccination in Danish Children Aged 5 to 11 Years. Pediatrics, v.150, n.2, 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35585684/. Acesso em: 13 jun. 2024.
PARK, H. et al. Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study. J Korean Med Sci, v.36, n.32, 2021. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34402230/. Acesso em: 13 jun. 2024.
PILLAY, J. et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. BMJ (Clinical research ed.), v. 378, p. e069445, 2022.
WATANABE, A. et al. Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-analysis. JAMA Pediatr, v. 177, n. 4, p. 384-394, 2023. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36689319/. Acesso em: 13 jun. 2024.
WOODRUFF, R. C.; CAMPBELL, A. P.; TAYLOR, C. A.; CHAI, S. J.; KAWASAKI, B.; MEEK, J. et al. Fatores de risco para COVID-19 grave em crianças. Pediatria, 149:e2021053418, 2022.
WU, C. T.; CHIN, S. C.; CHU, P. H. Miocardite fulminante aguda após vacina ChAdOx1 nCoV-19: relato de caso e revisão da literatura. Frontal Cardiovasc Med, 9:856991, 2022.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Gabriel dos Santos Medeiros, Maria de Fátima Trigueiro Silva, Francisca Evelyn Abreu de Lira, Camila de Oliveira Prata Pessoa, Ana Beatriz Vieira de Sousa, Ana Caroliny Suassuna de Aquino, Umberto Marinho de Lima Junior